Director Declaration

Clare Brady, Chairman of Fidelity Asian Values PLC, has been appointed a Non-executive Director of JPMorgan American Investment Trust plc effective 15 May 2026. The appointment was announced on 08 April 2026 by George Bayer, Company Secretary at FIL Investments International. This is a routine governance disclosure with no material financial impact expected.

Analysis

A chair or senior director holding additional listed-trust roles materially changes the governance signal investors price into closed‑end discounts. Market perception often treats such cross‑directorships as either a governance strength (knowledge transfer, benchmarking of manager terms) or as a governance dilution (time constraints, conflict of interest); pricing tends to re-rate within 3–9 months around AGM cycles and fee renegotiation windows. Expect discounts to be the primary transmission mechanism — a perceived weakening of oversight typically widens discounts by 200–500bps; conversely clear, demonstrable value‑add (e.g., securing better manager terms) tightens discounts by similar magnitudes.

Second‑order effects concentrate in liquidity and activist math: trustees with overlapping roles become target sets for activists because replacing a director requires an investable catalyst that activists can engineer (proxy contests, requisitions) and those campaigns compress available liquidity as large holders take positions. This raises funding and cost‑of‑capital risks for mid‑cap closed‑end funds over a 6–18 month horizon and can transiently bid up passive Asia exposures as retail/institutional buyers seek lower‑governance counterparty risk.

Key tail risks are reputational or regulatory — a single governance misstep (conflicted vote, poor time commitment disclosure) can produce >10% share price drawdowns in days and attract FCA/Listing Rule scrutiny over weeks. Reversal catalysts that would unwind a negative re‑rating include an independent review, an announced succession plan, or evidence of improved manager economics (fee cuts, performance‑linked fees) — each typically materializes within calendar quarters rather than intraday windows.

Key Decisions for Investors

• Long Fidelity Asian Values PLC (LON:FAS) — 3–9 month hold. Size as a modest (1–2%) idiosyncratic position to capture potential 200–400bps discount tightening if board demonstrates active oversight or announces succession/terms improvements. Risk: governance headline could widen discount 10–20%; use 6–8% stop loss from entry.
• Pair trade: long AAXJ (iShares MSCI Asia ex‑Japan ETF) / short EEM (iShares MSCI Emerging Markets ETF) — 1–6 month horizon. Isolate Asia ex‑Japan beta while hedging EM‑wide China/commodity exposure; target 6–10% relative return if Asian allocation flows re‑rate; theta risk modest, mark‑to‑market volatility 8–14% so size accordingly.
• Buy downside protection: AAXJ 3‑month 10% OTM puts (size 25–50% of net long AAXJ/FAS exposure) to cap event risk around governing‑board headlines. Cost is insurance: expect 1–2% of notional; this converts a tail 10–20% wholesale discount blowout into a defined loss and preserves optionality.
• Monitor and be ready to initiate short positions in trusts where dual roles correlate with measurable declines in board meeting attendance or disclosure (trigger: two consecutive AGM disclosures showing below‑median attendance). Entry signal: disclosure or third‑party report; target capture 15–30% downside within 3–12 months when activism or forced refresh becomes likely.